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Abstract
Background: The aberrant expression of microRNA-140-5p (miR-140-5p) has been described in gastric cancer (GC).
However, the role of miR-140-5p in GC remains unclear. In this study, the prognostic relevance of miR-140-5p in GC
was investigated and YES1 was identified as a novel target of miR-140-5p in regulating tumor progression.
Methods: miR-140-5p level was determined in 20 paired frozen specimens through quantitative real-time PCR, and
analyzed in tissue microarrays through in situ hybridization. The target of miR-140-5p was verified through a dual
luciferase reporter assay, and the effects of miR-140-5p on phenotypic changes in GC cells were investigated in
vitro and in vivo.
Results: Compared with that in adjacent normal tissues, miR-140-5p expression decreased in cancerous tissues.
The downregulated miR-140-5p in 144 patients with GC was significantly correlated with the reduced overall
survival of these patients. miR-140-5p could inhibit GC cell proliferation, migration and invasion by directly
targeting 3′–untranlated region of YES1. miR-140-5p could also remarkably reduce the tumor size in GC
xenograft mice.
Conclusions: miR-140-5p serves as a potential prognostic factor in patients with GC, and miR-140-5p mediated
YES1 inhibition is a novel mechanism behind the suppressive effects of miR-140-5p in GC.
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Background
Gastric cancer (GC) is a frequently diagnosed cancer and
considered a major contributor to health problems world-
wide [1, 2]. Although diagnostic approaches and treatment
strategies have improved gradually, the prognosis of pa-
tients with GC in advanced stages remains poor. Thus,
the causative mechanisms of GC tumorigenesis and
metastasis should be elucidated.
Aberrant signaling events frequently occur in human
malignancies and contribute to oncogenesis. For example,
upregulated Src signaling, which increases proportionally
with progressive TNM stages, has been reported in various
human cancers [3], and members of Src family tyrosineki-
nases (SFKs) are prototypical non-receptor protein tyro-
sine kinases. YES proto-oncogene 1(YES1), a notable
member of SFKs, serves as a seminal regulator of cell
growth, adhesion, and differentiation. The major role of
YES1 in tumor progression is supported by the decreased
YES1 expression correlated with the impaired growth
abilities of several malignancies, including malignant
mesothelioma, rhabdomyosarcoma, and pancreatic cancer
[4–6]. YES1 also provides chemotherapeutic resistance in
several cancers. For instance, YES1 can promote the nu-
clear translocation of the epidermal growth factor receptor
that induces resistance to cetuximab in the non-small cell
lung cancer line NCI-H226 [7]. However, the expression
level of YES1 in GC tissues remains controversial. Seki et
al. observed the upregulation of YES1 expression in GC
tissues compared with that in adjacent normal tissues, but
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Wang et al. obtained an opposite conclusion [8, 9]. In
addition to these inconsistent findings, the underlying
causes of aberrant YES1 expression in GC are unclear.
MicroRNAs (miRNAs) are an endogenous group of
small non-coding RNAs that post-transcriptionally re-
press the expression of protein-coding genes. miRNAs
function as specific repressors of translation or cleavage
inducers of RNA transcripts by complementarily binding
to the corresponding 3′ -untranslated region (3′-UTR)
of an mRNA transcribed from a protein-coding gene,
miRNAs regulate up to 60% of human protein-coding
genes [10], but specific miRNA subsets or clusters are
dysregulated in various tumors [11–13]. An example of
these miRNAs is miR-140-5p, whose various roles have
been widely explored. miR-140-5p has been character-
ized as a tumor suppressor in colorectal cancer, biliary
tract cancer and hypopharyngeal cancer [14–16]. In GC,
high miR-140-5p levels have been detected in the plasma
of patients, whereas low miR-140-5p levels have been
found in 20 tissue samples and a HGC-27 cell line [17,
18]. Nevertheless, the prognostic relevance and functions
of miR-140-5p in GC are largely unknown. Considering
that various protein coding genes are targeted by one
miRNA, researchers should determine the mechanisms
of miR-140-5p mediated phenotypic changes in GC cells.
This study aimed to evaluate the prognostic relevance
of miR-140-5p in GC and identify whether YES1 is a dir-
ect target of miR-140-5p in the regulation of tumor
progression.
Methods
Patients and tissue samples
Tissue specimens (tumor, adjacent gastric mucosa, and
normal tissues from a benign disease) were collected
and immediately frozen in liquid nitrogen by a patholo-
gist after informed consent was obtained from patients
in the First Affiliated Hospital of Anhui Medical Univer-
sity (Hefei, China). The tissue specimens consisted of 20
paired cancer and adjacent normal tissues from 144 pa-
tients with GC and 43 normal gastric mucosa tissues from
patients with a benign disease. Histological cancer types
were evaluated by at least two independent pathologists in
accordance with the TNM staging guide (2010) released
by The American Joint Committee on cancer (AJCC). The
patients’ characteristics are presented in Additional file 1:
Tables S1 and Additional file 2: Table S2. None of the pa-
tients received preoperative chemoradiotherapy. Clinical
follow-up consisted of telephone calls and reviews of clin-
ical data, including age, gender, tumor location and size.
The dates of patients’ death were documented and the
overall survival (OS) was defined as the time from the op-
eration date to the date of death. All of the experiments in
this study were approved by the Ethics Committee of
Anhui Medical University.
RNA extraction and quantitative real-time PCR (qRT-PCR)
analysis
Total RNA was extracted from fresh tissue specimens or
cells and assayed for mature miRNAs by using TRIzol
reagent (Invitrogen, USA). cDNAs were generated using
MMLV reverse transcriptase (Takara, Japan). (qRT-PCR)
was run in an IQ5 Real-time PCR detection system
(Applied Biosystems, USA), with a SYBR Premix Ex
Taq kit (Takara, Japan). The sequences of the primers
were listed as follows: miR-140-5p forward primer 5-´
TGCGGCAGTGGTTTTACCCTATG- 3′ and reverse
primer 5′- CCAGTGCAGGGTCCGAGGT -3′. U6 for-
ward primer 5-´TGCGGGTGCTCGCTTCGGCAGC- 3′
and reverse primer 5′-CCAGTGCAGGGTCCGAGGT -3′.
The reactions were incubated at 94 °C for 4 min followed
by 40 cycles of 94 °C for 30 s, 58 °C for 30 s and 72 °C for
30 s. Relative expression was achieved by comparative CT
calculation (2-ΔΔCt method) and normalized to U6-snRNA.
All of the experiments were performed at least in triplicate.
miRNA In situ hybridization (ISH)
The tissue sections were dewaxed, rehydrated, digested
with 15 μg/mL proteinase K, and incubated with a double-
DIG- labeled LNA microRNA probe (Exiqon, Denmark)
for miR-140-5p with positive U6 (Exiqon, Denmark) and
negative scrambled LNA probes as controls. The staining
intensities of the tumor cells or normal epithelial cells
were scored by two independent pathologists in accord-
ance with the following descriptions: 0, negative, 1, weakly
positive, 2 moderately positive and 3 strongly positive
[19–21]. Scores ≥2 were designated as “high expression”,
whereas scores <2 were defined as “low expression”.
Cell culture and miRNA transfection
Human cell lines (AGS, MKN45, BGC823, MGC803,
SGC7901, GES1 and 293 T) were derived from ATCC
(Manassas, Virginia, USA). AGS, MKN45, BGC823,
MGC803, and SGC7901 were the five GC cell lines,
while GES1 was the immortalized gastric epithelial cell
line. AGS, MGC803, GES1 and 293 T cells were cultured
in DMEM (Gibco BRL, USA) supplemented with 10%
fetal bovine serum (FBS, Gibco BRL, USA), and incu-
bated at 37 °C in a humidified chamber with 5% CO2.
BGC823, MKN45, and SGC7901 cells were maintained
in RPMI 1640 medium (Gibco BRL, USA) with 10%
FBS, (Gibco BRL, USA). 293 T cells were transfected
with empty pcDNA3.1(+) or constructed pcDNA3.1(+)/
YES1 vectors (Saierbo, Tianjin, China). AGS and BGC823
cells were transfected with miR-140-5p or negative control
mimics (Gene-Pharma, Shanghai, China) by using Lipofec-
tamine2000 Reagent (Invitrogen, USA) in accordance
with the manufacturer’s protocol. Afterward, the GC
cells were further transfected with empty pcDNA3.1(+)
or pcDNA3.1(+)/YES1 vectors for rescue assays.
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Western blot
GC cells were lysed with RIPA buffer (Beyotime, Jiangsu,
China) in an ice bath for 30 min. The lysate was centri-
fuged at 12,000 rpm for 20 min, and the supernatant
was collected. The protein samples in the supernatant
were denatured, separated by 10% sodium dodecyl sul-
fate -polyacrylamide gel-electrophoresis, and transferred
onto polyvinylidenedifluoride membranes (Millipore, MA,
USA). The membranes were then blocked with 5% skim
milk for 1 hand incubated with primary antibodies against
YES1, Ki-67, cyclinD1, survivin, E-cadherin, vimentin,
Snail, MMP2, MMP3 and SOX4 (1:200, Saierbo, Tianjin,
China) at 4 °C overnight. Afterward, the membranes were
washed with Tris-buffered saline and incubated with
secondary horseradish peroxidase (HRP-) labeled goat
anti-rabbit IgG antibodies (1:10,000, Saierbo, Tianjin,
China) for 2 h. β-tubulin (1:500.Saierbo, Tianjin, China)
was used as control. The protein bands on the mem-
branes were then detected using Western Lightning
Chemiluminescence Reagent (PerkinElmer, USA) and
photographed through LabWorksGel imaging and ana-
lysis system (UVP, USA).
Dual luciferase reporter assay
HumanYES1 3′ UTR (Accession number NM_014143
for YES1), and mutant YES1 3′ UTR were cloned with
the following primers: underlined letters corresponded
to the mutated sequences and bold letters indicated the
sites cut by PmeI or Xbal).
YES1–3′ UTR wild-type:
Forward:5′-AAAC TAGCGGCCGC TAGT
TATGGTTGCACAAAACCACTT T -3′,
Reverse: 5′-CTAGA AAGTGGTTTTGTGCAACCATA
ACTA GCGGCCGCTAGTTT-3′
YES1–3′ UTR mutant:
Forward: 5′-AAAC TA GCGGCCGC TAGT
TATGGTTGCACATATCGAGAT T-3′,
Reverse: 5′-CTAGA ATCTCGATATGTGCAACCATA
ACTA GCGGCCGCTAGTTT-3′
The fragment of the wild type or mutant YES1 3′
UTR was ligated into a pmirGLO -dual-luciferase miRNA
target expression vector (Promega, USA). The constructed
vectors were validated by sequencing, cloned, and purified.
AGS was then co-transfected with the constructed vectors
and miR-140-5p mimics or miR-NC mimics (GenePharma,
Shanghai, China) and then cultivated for 48 h. Luciferase
activity was subsequently measured using the Dual Lucifer-
ase Reporter Gene Assay Kit (Beyotime, Jiangsu, China) in
accordance with the manufacturer’s protocol. The relative
light unit of the firefly luciferase was recorded with a
GloMax 96 microplate luminometer (Promega, USA).
The ratio of firefly to Renilla was used to normalize the
firefly luciferase values.
Cell proliferation assay
After transfection was conducted, MTT assay was per-
formed for 24, 48, or 72 h in accordance with the manu-
facturer’s manual. In brief, 100 μL of a culture medium
containing 1 × 104 GCcells were added to each well of a
96well plate. After 12 h of cultivation, 10 μL of MTT so-
lutions were added into each well and incubated for 4 h.
Afterward, 100 μL of a detergent reagent was added, and
the plate was incubated in the dark at room temperature
for 2 h. Absorbance at 490 nm in each well was recorded
using a microplate reader (Bio-tek, USA).
Colony formation assays
GC cells were suspended in DMEM containing 10% FBS
and 0.3% low- melting-point agarose. A total of 500 cells
were then seeded into each well of a 12-well plate coated
with 0.5% agarose. After 14 days of cultivation, colonies
were stained with 0.1% crystal violet and counted.
Wound healing assays
GC cells were suspended and seeded into each well of
a12-well plate at a density of 1 × 105/cm2. After the cells
attached to the bottom and formed a monolayer, linear
wounds were scratched with a pipette tip at the center
of the monolayer The detached cells were carefully
washed off with PBS thrice. Afterward, 1 mL of DMEM
(Gibco BRL, USA) containing2%FBS (Gibco BRL, USA)
was added into each well, and the wounds were photo-
graphed at 0,2,48, and 72 h under a microscope (Olym-
pus, Japan) and the widths of each scratch wound were
recorded.
Transwell assays
Invasion assay was performed in 24-well Transwell
chambers (Millipore, USA) in accordance with the man-
ufacturer’s manual. In brief, the invasion chamber was
pre-coated with 10 μL of fibronectin(Sciencell, USA)
and loaded with 50 μL of Matrigel (BD, USA). After the
coated plate was incubated at 37 °C for 2 h, 0.5 mL of
cell suspension without serum (1 × 105 cells) was added
to the invasion chamber and 500 μL DMEM with 10%
FBS, (Gibco BRL, USA) was added to the lower cham-
ber. The plate was then incubated at 37 °C for 24 h, and
the cells on the outer surface of the insert bottom were
fixed, stained with crystal violet, and counted under a
microscope at 100× magnification.
In vivo xenograft study
A mouse xenograft model was established in 6 week- old
BALB/c-nu mice (Model Animal Research Institute of
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the Chinese Academy of Medical Sciences, Beijing, China)
in accordance with the institutional guidelines. In brief,
5 × 106 BGC823 cells suspended in 100 μL of PBS were
injected subcutaneously into the left dorsal flanks of
the mice. When the tumor size reached approximately
50 mm3, 18 mice were equally divided into the follow-
ing three groups: group A as blank control, group B as
miR-140-5p treatment, and group C as control mimic
treatment. Each tumor in group B or C was injected
with50 μL solution containing 7 nmol miRNA mimics,
3 μL of Lipofectamine2000 (Invitrogen), and 40 μL of
serum-free medium Opti-MEM (Invitrogen). After the
treatments were administered, the length (L) and width
(W) of the tumors were measured every 3 days, and the
mice were weighed every 4 days. Tumor volume (V)
was calculated using the following eq. V = 0.5 × L × W2.
On day 19 the mice were sacrificed and the tumors
were dissected, weighed and photographed. The tumor
tissues were fixed in 4% paraformaldehyde for further
studies.
Immunohistochemistry
The tumor tissues of the mice were fixed, embedded in
paraffin. And sliced into consecutive tissue sections.
Next, 5 μm thick tissue sections were deparaffinized,
dehydrated, and heated in citrate buffer (pH 6.0) for
15 min at 95 °C. To block the nonspecific bindings of
the first antibody, we added 1% bovine serum onto the
slides for 20 min at room temperature. The tissue sec-
tions were then incubated with YES1 antibodies (1:50;
Saierbo, Tianjin, China) overnight at 4 °C, and subse-
quently incubated with the secondary HRP-labeled goat
anti-rabbit IgG antibodies (1:20,000, Saierbo, Tianjin,
China). Finally, the sections were visualized with a DAB
kit (ZSGB-bio, Beijing, China) and counterstained with
hematoxylin (Beyotime, Jiangsu, China).
Statistical analysis
Data were statistically analyzed using GraphpadPrism5.
The relative expression of miR-140-5p in the GC tissues
and adjacent normal tissues was presented as median
(interquartile range) through a nonparametric test (Wil-
coxon’s test). Other measurement data were described as
means ± standard error of means.
The correlations between miR-140-5p level and the
pathologic parameters were analyzed through Pearson’s
χ2 test, and the survival and OS curves were plotted
using the Kaplan–Meier method. Student’s t test was
used to evaluate the differences between two groups,
and one-way (ANOVA) was preformed to compare more
than two groups. All P-values were two-sided and differ-
ences were considered significant when P < 0.05. *, **,
or *** corresponded to P < 0.05, P < 0.01, or P < 0.001,
respectively.
Result
miR-140-5p is downregulated in GC tissues and correlated
with the patients’OS
We investigated miR-140-5p expression in 20 fresh GC
tissues and matched adjacent normal tissues through
qRT-PCR and found that the miR-140-5p expression
was significantly downregulated in the tumor tissues
(P < 0.001) (Fig. 1a-b). Subsequent ISH analysis of the
miR-140-5p levels in the 144 GC tissues and 43 normal
gastric tissues revealed similar results (Fig. 1c). The
staining intensities of miR-140-5p were reduced in 32.6%
of the GC tissues (47 of 144).By comparison, 11.6% (5 of
43) of the normal gastric tissues showed downregulations
(P = 0.007). A Cox proportional hazards regression model
was established to examine the prognostic significance of
miR-140-5p and other clinical parameters. In addition to
tumor differentiation, invasion depth and lymph node me-
tastasis, miR-140-5p level was an independent favorable
predictor of OS (Additional file 2: Table S2). Further cor-
relation analysis demonstrated that the downregulated
miR-140-5p levels were correlated with the reduced OS of
the patients with GC (P = 0.0084; Fig. 1d). The median
survival times (20 months) of the patients with low miR-
140-5p expression were shorter than those (59 months)
with high miR-140-5p expression.
miR-140-5p directly targets one evolutionarily conserved
sequence within the 3′UTR of YES1
To investigate the potential target of miR-140-5p, we
combined the results from prediction databases (Tar-
getScan, miRDB, and ComiR) and found that YES1 was
a possible target (Fig. 2a). We then utilized a panel of
five GC cell lines and one normal gastric cell line to ver-
ify the predicted results. We initially screened the miR-
140-5p expression in these cell lines (Fig. 2b) and then
confirmed the inverse correlation between miR-140-5p
level and YES1 protein expression in AGS and BGC823
cells (P < 0.05; Fig. 2c-d). Next, we performed luciferase
reporter assay to investigate whether the 3′-UTR of the
YES1 gene was a direct target of miR-140-5p in GC. The
transient transfection of AGS cells with miR-140-5p
and YES1 3′-UTR plasmids revealed that the relative
luciferase intensity was significantly decreased com-
pared with that of the miRNA control. By contrast, the
vector containing the site mutated 3′-UTR sequence
was not affected by miR-140-5p (Fig. 2e). These results
indicated that 3′-UTR of YES1 was a direct target of
miR-140-5p.
miR-140-5p suppresses the cell proliferation, migration,
and invasion of GC in vitro
To determine the effects of miR-140-5p on GC cell
proliferation, we performed MTT assays and colony
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formation assays. Compared with those of the control
groups in vitro, the transfection-induced overexpression
of miR-140-5p in AGS and BGC823 cells significantly
suppressed the proliferation ability of GC cells over
time (Fig. 3a). The colony formation assays demon-
strated that the AGS and BGC823 cells transfected with
miR-140-5p showed remarkably decreased colony for-
mation abilities in comparison to those in the control
groups (Fig. 3b). Next, we investigated whether miR-140-
5p affects GC cell migration and invasion. Wound healing
assays showed that the miR-140-5p overexpressing cells
were less effective than the non-transfected cells in closing
an artificial wound over a confluent monolayer (Fig. 3c).
We also examined the influence of miR-140-5p on GC
cell invasion by Transwell assay (Fig. 3d). and ob-
served that the numbers of GC cells invading through
the Matrigel were remarkably decreased after these
cells were treated with miR-140-5p compared with
those in the negative control. These results suggested
that miR-140-5p attenuated the migration and inva-
sion of GC cells.
miR-140-5p regulates genes associated with tumor
proliferation, migration, and invasion in vitro
Western blot assays were performed to detect the expres-
sion of the markers associated with the tumor prolifera-
tion, migration, and invasion of AGS and BGC823 cells
and to clarify the mechanisms of the inhibitory effects of
miR-140-5p on GC cells. After miR-140-5p treatment was
administered, the protein levels of Ki-67, CyclinD1,
vimentin, Snail, MMP2, and MMP3 were remarkably de-
creased, whereas the protein level of E-cadherin was sig-
nificantly increased in both cells. However, the increased
level of survivin was observed only in BGC823 cells,
whereas no remarkable changes were found in AGS cells.
We further verified that the level of SOX4, which has been
reported as a direct target of miR-140-5p in HGC-27, was
reduced in both cells (Fig. 3e).
Fig. 1 Decreased miR-140-5p expression in tumor tissues correlates with the poor survival of gastric cancer (GC) patients. a-b miR-140-5p
expression significantly decreased in the cancer tissues relative to that in the adjacent normal tissues (b presents the medians and interquartile
ranges). c Representative images of in situ hybridization for miR-140-5p in GC tissues and adjacent normal tissues: a, b high miR-140-5p level in
cancerous epithelia; c, d low miR-140-5p level in cancerous epithelia; e, f high miR-140-5p level in normal gastric epithelia. The arrows in b
and f orient the strong miR-140-5p staining in cancerous epithelia or normal gastric epithelia, whereas those in d show weak staining in the
cancerous epithelia. Magnification:200 × (a, c, e) and 400 × (b, d, f). d Overall survival (OS) curves for patients with GC with the log-rank test.
Kaplan–Meier survival analysis of the relationship between different miR-140-5p levels and OS of 144 patients with GC
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Reconstitution of YES1 rescues the miR-140-5p-mediated
inhibition in GC cells
To examine whether miR-140-5p elicits inhibitory ef-
fects on GC cells through YES1, we transfected the
constructed YES1 expression vectors with miR-140-5p
(Fig. 4a-b). Subsequent MTT and colony forming assay
revealed that reintroducing YES1 restored the miR-140-
5p-mediated growth repression of GC cells (Fig. 4c-d).
Likewise, the repressive effect of miR-140-5p on GC cell
migration and invasion could be rescued by reconstituting
YES1 (Fig. 5a-c). Collectively, these data provided evidence
that miR-140-5p partially repressed the proliferation, mi-
gration and invasion of GC cells by inhibiting YES1.
miR-140-5p suppresses the growth of BGC-823 xenograft
tumors
On the basis of our in vitro results, we further explored
the inhibitory potential of miR-140-5p on GC growth in
vivo. BGC-823 cells were subcutaneously implanted into
the flank of nude mice and the size of the xenograft tu-
mors was measured after miR-140-5p mimics or control
mimics with a blank control were intratumorally
injected. The growth curve tended toward lower tumor
volumes in the miR-140-5p group than in the control
groups (Fig. 6a). Subsequently, the xenograft tumors
were harvested and weighed immediately after the mice
were sacrificed. Consistent with the tumor volume, the
mean tumor mass was significantly lower in the miR-140-
5p group than in the control groups (Fig. 6b-c). The YES1
levels in the tumor tissues were than examined through
immunohistochemistry staining. In line with the in vitro
results, YES1 protein staining was evidently weaker in the
miR-140-5p-treated tumors than in the control tumors
(Fig. 6d).
Discussion
Compared with that in adjacent normal tissues, miR-
140-5p was downregulated in GC tissues. Similar results
were also observed in the GC cell lines compared with
those in the nonmalignant cell line. This study is the
first to show the correlation between the downregulated
expression of miR-140-5p in GC and the reduced mean
survival of patients with this disease. We also demonstrated
that miR-140-5p directly targeted 3′ UTR-YES1 and the
downregulated miR-140-5p was partly responsible for the
upregulation of YES1. Moreover, the forced miR-140-5p
Fig. 2 miR-140-5p directly targets YES1 in GC cells. a miR-140-5p binding sites of YES1 3′ UTR predicted by the database Targetscan. b Expression
levels of miR-140-5p determined by quantitative real-time PCR in five GC cell lines and one normal human gastric epithelial cell line GES1.
c Quantification real-time PCR verification of overexpression after miR-140-5p transfection in AGS and BGC823 cells. d Western blot of YES1
protein in GC cells after miR-140-5p or control mimics transfection. e Relative luciferase activity in AGS cells co-transfected with miR-140-5p or
control mimics together with reporter vectors carrying wild-type (WT) or mutated-type (MT) YES1 3′ UTR
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expression significantly inhibited GC cell proliferation, mi-
gration and invasion by inhibiting YES1 in vitro. Intratu-
moral miR-140-5p injected into the xenograft tumors of
the nude mice significantly impeded tumor growth.
A previous study similarly concluded that miR-140-5p
levels decrease in GC tissues compared with those in
normal tissues. In addition to YES1, other targets, such
as SOX4, are downregulated by increased miR-140-5p in
HGC-27 [18]. However, these data were obtained from
20 GC samples and 1 GC cancer cell line. Studies with
large sample sizes are required to further corroborate
these findings. In our study, the ISH staining results of
TMA from the144 patients are consistent with the conclu-
sions of other groups. We demonstrated that low miR-140-
5p levels in GC tissues predicted the poor clinical outcomes
of patients, and we suggested that miR-140-5p could be a
potential prognostic factor. Unfortunately, we did not con-
serve the blood sample of the patients enrolled in the TMA
study and thus failed to verify the previous description of
serum miR-140-5p levels in patients with GC. To achieve
translational application, we will further investigate the cor-
relation of serum miR-140-5p levels with patient prognosis.
Fig. 3 miR-140-5p inhibits GC cell proliferation, migration and invasion in vitro. a Effect of miR-140-5p on GC cell growth determined by MTT
assays. b Colony formation assays in GC cells transfected with miR-140-5p or control mimics. Data are representative of at least three independent
experiments; values are expressed as means ± standard errors of the means (SEMs). c Wound healing assays showing the inhibition of miR-140-5p on
the migratory abilities of GC cells. d Transwell assays in GC cells transduced with miR-140-5p or control mimics. Data are representative of at least three
independent experiments; values are expressed as means ± SEMs. e Western blot analysis of markers associated with tumor proliferation, migration,
and invasion, as well as SOX4, after miR-140-5p transfection in vitro
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Previous studies suggested the diversity of miR-140-5p
mediated effects on tumor cell phenotypes. For instance,
miR-140-5p suppresses the self-renewal and growth of
breast cancer stem cells [22] and inhibits the invasion of
esophageal cancer cells rather than their proliferation
[23]. However, studies have yet to clarify whether miR-
140-5p can induce phenotypic changes, in addition to its
inhibitory effects on tumor cell proliferation, in GC.
Cancer cell lines might also respond differently to the
same treatment because of their genetic variances. As
such, additional functional experiments are necessary to
support previous conclusions. In the two cell lines ob-
served in our study, miR-140-5p inhibited not only the
proliferation of GC cells but also their migration and
invasion. These results were further validated by the re-
duced levels of phenotype-related proteins, including
Ki-67 and cyclinD1 (proliferation) [24], vimentin and
Snail (migration) [25], and MMP2 and MMP3 (cell in-
vasion) [26, 27]. E-cadherin levels were also increased,
and this finding implied that the cell-to-cell adhesion
abilities of GC cells are enhanced [28]. Considering the
same phenotypic changes of both cell lines, the incon-
sistent changes of survivin (cell division) levels were
possibly due to the different cell line backgrounds; this
topic requires further research. Moreover, the upregula-
tion of survivin in BGC823 cells, which indicates the
increased abilities of cell division, seemed to be contrary to
the growth inhibition phenomenon after miR-140-5p treat-
ment [29]. Thus, we speculate that cell division process
might not be the key procedures interfered by miR-140-5p.
Additionally, in vitro assays may be unable to show the ac-
tual biological processes of tumor cells in complex micro-
environments. Thus, we detected the suppressive effect of
miR-140-5p by using a nude mouse model. Consistent with
our in vitro findings, our observations in the mouse model
revealed that miR-140-5p impeded the growth of GC
tumor grafted in nude mice.
YES1 is suppressed by miRNAs in the tumor progres-
sion of oral cancer, ovarian cancer, and hepatocellular
carcinoma, and this observation indicates that YES1 may
be regulated by miRNAs in GC [30–32]. Although in
silico analysis suggests that YES1 is a target gene of
miR-140-5p, neither the putative interaction nor the
functional role of YES1 in GC has been defined. Our re-
sults show that miR-140-5p directly targeted the 3′-UTR
of the YES1 gene, because its overexpression was signifi-
cantly associated with luciferase activity suppression. A sig-
nificant decrease in YES1 protein expression was validated
after miR-140-5p was overexpressed in GC cells. Likewise,
miR-140-5p injections reduced the immunohistochemical
staining density of theYES1 protein in the transplanted
tumors of nude mice.
Fig. 4 Overexpressing YES1 restores the viability of GC cells in vitro. a YES1 protein level of 293 T cells in response to YES1 overexpressing
plasmids [pcDNA3.1(+)] or empty vector. b Restoration of YES1 expression in GC cells after miR-140-5p treatment as determined by Western blot
analysis. c-d MTT and colony formation assays after overexpressing YES1 in GC cell
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Considering the importance of YES1 in solid cancer,
we further characterized its role by overexpressing the
YES1 protein. YES1, which is a SFK family member, plays
a pleiotropic role in oncogenic cell functions. Rosenbluh
et al. .confirmed that YES1 promotes the phosphorylation
of YAP1 and the proliferation of cancer cells by activating
the Wnt/β-catenin pathway [33]. YES1 upregulation simi-
larly reverses the miR-140-5p-mediated inhibition of GC
cell growth and colony formation. Liu et al. reported that
activating YES1 enhances the metastatic behaviors of mel-
anoma cells [34]. Overexpressing YES1 reverses the inhibi-
tory effects of miR-140-5p on GC cell migration and
invasion. We also demonstrated the role of YES1 in the
multiple oncogenic activities of GC cells. Interestingly, the
co-transfection of YES1-overexpressing vectors with
miR-140-5p did not fully revert the suppressive behavior
of GC induced by miR-140-5p. This phenomenon could
be possibly attributed to the ability of miR-140-5p to dir-
ectly target other important oncogenic genes, such as
SOX4. Previous studies confirmed that miR-140-5p sup-
presses GC cell proliferation by targeting SOX4, and this
finding was supported by our results, which demonstrated
that miR-140-5p overexpression decreased the protein
levels of SOX4 in AGS and BGC823 cells. Unfortunately,
SOX4 has been reportedly associated with the prolifera-
tion phenotype of HGC-27 only, and this observation may
Fig. 5 Overexpressing YES1 restores the mobility of GC cells in vitro. a-b Wound healing assays after YES1 re-expression in GC cells. c Transwell
invasion assays after YES1 reconstitution in GC cells
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not explain why YES1 only partially restores the mi-
gratory and invasive phenotypes suppressed by miR-
140-5p. We inferred that other published miR-140
targets, such as ADAMTS5 and IGFBP5 in colorectal
cancer [35], Pin1 in liver cancer [36], and IGF2BP1 in
cervical cancer [37], which are associated with tumor mi-
gration and invasion, may contribute to these GC cell phe-
notypes. However, further studies should identify the novel
pathways by which miR-140-5p mediates its inhibitory ef-
fects on GC because of the genetic diversities of different
tumors, and the genetic variances of different cell lines from
the same tumor type.
Conclusions
This study is the first to report that miR-140-5p serves
as a potential prognostic factor for patients with GC and
inhibits GC tumorigenesis by directly targeting YES1.
Our study provides further insights into the pathogen-
esis of GC and basis for improvements of therapeutic
approaches.
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